

IN THE UNITED STATES DISTRICT COURT
FOR THE DISTRICT OF DELAWARE

SANTEN PHARMACEUTICAL CO., LTD.,)
ASAHI GLASS CO., LTD., and OAK)
PHARMACEUTICALS, INC.,)
)
Plaintiffs,)
)
v.) C.A. No. _____
)
MICRO LABS LIMITED, and MICRO)
LABS USA INC.,)
)
Defendants.)

COMPLAINT

Plaintiffs Santen Pharmaceutical Co., Ltd. (“Santen”), Asahi Glass Co., Ltd. (“AGC”), and Oak Pharmaceuticals, Inc. (“Oak”) (collectively, “Plaintiffs”), for their Complaint against Defendants Micro Labs Limited (“Micro Labs LTD”) and Micro Labs USA Inc. (“Micro Labs USA”) (together, “Micro Labs”), allege as follows:

NATURE OF THE CASE

1. This is an action for patent infringement under the patent laws of the United States, Title 35, United States Code, arising from Micro Labs’ filing of an Abbreviated New Drug Application (“ANDA”) with the United States Food and Drug Administration (“FDA”), in which Micro Labs seeks FDA approval to manufacture and sell a generic version of Plaintiffs’ ZIOPTAN® (tafluprost ophthalmic solution) 0.0015% (“ZIOPTAN®”) prior to the expiration of U.S. Patent No. 5,886,035 (“the ‘035 Patent”).

2. By letter dated April 5, 2016, Micro Labs USA notified Plaintiffs that Micro Labs LTD had filed ANDA No. 209051 (“Micro Labs ANDA”), seeking FDA approval to

manufacture and sell a generic version of Plaintiffs' ZIOPTAN® prior to the expiration of the '035 Patent.

THE PARTIES

3. Plaintiff Santen is a Japanese corporation, having a principal place of business at 9-19, Shimoshinjo 3-chome, Higashiyodogawa-ku, Osaka, Japan.

4. Plaintiff AGC is a Japanese corporation, having a principal place of business at 1-5-1, Marunouchi, Chiyoda-ku, Tokyo, Japan.

5. Plaintiff Oak is a Delaware corporation, having a principal place of business at 1925 West Field Court, Suite 300, Lake Forest IL 60045.

6. On information and belief, Defendant Micro Labs LTD is an Indian corporation, having a principal place of business at 27 Race Course Road, Bangalore 560001, India.

7. On information and belief, Defendant Micro Labs USA is a New Jersey corporation, having a principal place of business at 104 Carnegie Center, Suite 216, Princeton, NJ 08540.

8. On information and belief, Micro Labs USA is a wholly owned subsidiary of Micro Labs LTD, and is controlled and/or dominated by Micro Labs LTD.

9. On information and belief, Micro Labs LTD and Micro Labs USA are agents of each other and/or operate in concert as integrated parts of the same business group, and enter into agreements with each other that are nearer than arm's length.

10. On information and belief, Micro Labs LTD and Micro Labs USA regularly transact business within Delaware, including but not limited to, through Micro Labs LTD's direction of the operations and management of Micro Labs USA, as well as shipping generic

drugs to Micro Labs USA from locations outside the United States for marketing, sale and distribution by Micro Labs USA within the United States generally, and Delaware specifically.

JURISDICTION AND VENUE

11. This action arises under the patent laws of the United States of America, Title 35, United States Code. This Court has subject matter jurisdiction pursuant to 28 U.S.C. §§ 1331 and 1338(a).

12. Micro Labs LTD is subject to personal jurisdiction in this District, because, *inter alia*, it, on information and belief, regularly transacts business in this District and has engaged in systematic and continuous business contacts within the State of Delaware, and its suit-related conduct, *i.e.*, the Micro Labs ANDA seeking FDA approval to manufacture and sell a generic version of ZIOPTAN® in the United States, including in Delaware, creates a substantial connection with Delaware, and also demonstrates Micro Labs LTD's plans to direct sales of its generic drugs into Delaware. Moreover, Micro Labs LTD has consented to jurisdiction in Delaware (and has filed counterclaims) in other similar actions, in which Micro Labs LTD has been accused of infringement in connection with the filing of ANDAs seeking FDA approval to manufacture and sell generic drugs. *See, e.g., Bayer Intellectual Prop. GmbH et al. v. Aurobindo Pharma Ltd. et al.*, No. 1:15-cv-00902-SLR (D. Del.); *Alcon Research, Ltd. v. Micro Labs Ltd. et al.*, No. 1:14-cv-00014-SLR (D. Del.).

13. Micro Labs USA is subject to personal jurisdiction in this District, because, *inter alia*, it, on information and belief, regularly transacts business in this District and has engaged in systematic and continuous business contacts within the State of Delaware, and, on information and belief, it has acted in concert with Micro Labs LTD to file the Micro Labs ANDA, and will continue to act in concert to manufacture and sell a generic version of ZIOPTAN® in the United

States, including in Delaware. Micro Labs USA has also consented to jurisdiction in Delaware (and has filed counterclaims) in other similar actions, in which Micro Labs USA has been accused of infringement in connection with the filing of ANDAs by Micro Labs LTD seeking FDA approval to manufacture and sell generic drugs. *See, e.g., Bayer Intellectual Prop. GmbH et al. v. Aurobindo Pharma Ltd. et al.*, No. 1:15-cv-00902-SLR (D. Del.); *Alcon Research, Ltd. v. Micro Labs Ltd. et al.*, No. 1:14-cv-00014-SLR (D. Del.).

14. Venue is proper in this District pursuant to 28 U.S.C. §§ 1391 and 1400(b).

THE '035 PATENT AND ZIOPTAN

15. On March 23, 1999, the United States Patent and Trademark Office (“PTO”) issued the ‘035 Patent, entitled “Difluoroprostaglandin Derivatives and Their Use,” to AGC and Santen, the co-assignees of the named inventors, Eiichi Shirasawa, Masaaki Kageyama, Tadashi Nakajima, Takashi Nakano, Nobuaki Mori, Hideshi Sasakura, Yasushi Matsumura, and Yoshitomi Morizawa. Plaintiffs Santen and AGC are the record owners of the ‘035 Patent, and Plaintiff Oak is a licensee in relation to the sales and marketing of tafluprost in the United States. A copy of the ‘035 Patent is attached hereto as Exhibit A.

16. The original expiration date of the ‘035 Patent was December 18, 2017.

17. On February 23, 2016, the PTO issued a Certificate Extending Patent Term Under 35 U.S.C. § 156, extending the expiration date of the ‘035 Patent by 5 years to December 18, 2022.

18. On February 10, 2012, FDA approved New Drug Application (“NDA”) No. 202514 for ZIOPTAN®. Plaintiff Oak is the holder of NDA No. 202514 for ZIOPTAN®.

19. In the publication entitled “Approved Drug Products with Therapeutic Equivalence Evaluations” (known as the “Orange Book”), the ‘035 Patent is listed as covering ZIOPTAN®.

THE MICRO LABS ANDA

20. On information and belief, Micro Labs LTD and Micro Labs USA seek to constantly expand the range of generic products sold by them.

21. On information and belief, Micro Labs LTD and Micro Labs USA collaborate in the manufacture, marketing and sale of many pharmaceutical products (including generic drug products manufactured and sold pursuant to an approved ANDA) within the United States generally, and the State of Delaware specifically.

22. On information and belief, Micro Labs LTD and Micro Labs USA actively review pharmaceutical patents and seek opportunities to challenge those patents.

23. On information and belief, Micro Labs LTD and Micro Labs USA reviewed the ‘035 Patent and certain commercial and economic information relating to ZIOPTAN®, including estimates of the revenues generated by the sale of ZIOPTAN®, and decided to file an ANDA, seeking approval to market a generic version of ZIOPTAN®.

24. On information and belief, Micro Labs LTD and Micro Labs USA collaborated in the research, development, preparation and filing of the Micro Labs ANDA.

25. On information and belief, Micro Labs LTD submitted to FDA the Micro Labs ANDA seeking approval to engage in the commercial manufacture, use, and sale of a generic version of ZIOPTAN®, prior to the expiration of the ‘035 Patent.

26. Plaintiffs have received a letter dated April 5, 2016 from Micro Labs USA notifying them that the Micro Labs ANDA includes a certification under 21 U.S.C.

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.